Ambrisentan Tablet, Film Coated
Product Images NDC 51407-595

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Ambrisentan (NDC 51407-595). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Mock (51407-594-30LB)

Mock (51407-594-30LB)
This is a description of a medication called Ambrisentan in tablet form with a dosage of 5 mg per tablet. The medication guide can be printed from the given website. It is advised to dispense in a tight container, not to split, crush, or chew the tablets, and to keep out of children's reach. The tablets should be stored at temperatures between 20°C-25°C (68°F-77°F), with excursions permitted from 15°C-30°C (59°F-86°F). The medication is distributed by GSMS, Incorporated in Camarillo, California.*
FDA Label Image

Mock (51407-595-30LB)

Mock (51407-595-30LB)
This is a description of Ambrisentan tablets, NDC 51407-595-30. Each film-coated tablet contains 10 mg of ambrisentan. The usual dosage instructions can be found in the package insert. These tablets should not be split, crushed, or chewed. It is recommended to store the medication in a tight container at 20° - 25°C (68° - 77°F), with excursions permitted from 15°C - 30°C (59°F - 86°F). The medication should be kept out of reach of children and dispensed only in the original container. The pharmacist is advised to dispense the Medication Guide to each patient. For more information, the Medication Guide can be printed at https://gsms.us/.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
This appears to be a document detailing the ARIES-1 and ARIES-2 studies, including baseline measurements at Week 4, Week 8, and Week 12. The studies may involve different groups or dosages represented as meters and mg.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
This text includes data from two trials named ARIES-1 and ARIES-2. The information provides a comparison between Ambrisentan and Placebo treatments over a 12-week period. Each trial includes the number at risk in each group at different time points. The results suggest that Ambrisentan may have a positive effect, as compared to Placebo, based on the presented percentages.*
FDA Label Image

Structure (Structure)

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.